Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus

We have evaluated the efficacy of dapagliflozin in patients with type 1 diabetes mellitus (DM1) without adequate control. We expected that adding dapagliflozin to this population on top of their base treatment would lower their HbA1c levels. We conducted a pragmatic, open, 24-week study of treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamez, Hector E., Tamez, Alejandra L., Garza, Lucas A., Hernandez, Mayra I., Polanco, Ana C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600276/
https://www.ncbi.nlm.nih.gov/pubmed/26457255
http://dx.doi.org/10.1186/s40200-015-0210-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600276/
https://www.ncbi.nlm.nih.gov/pubmed/26457255
http://dx.doi.org/10.1186/s40200-015-0210-x

Ejemplares similares